SANDOZ' TAVIST-1 AND TAVIST-D RECOMMENDED FOR Rx-TO-OTC SWITCH APPROVAL: LABELING SHOULD INCLUDE HIGHLIGHTED DROWSINESS WARNING - - FDA ADVISORY CMTE.

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".